

**Supplemental Digital Content 3. Participant and maternal baseline characteristics, caregiver-reported adherence measures, and correlates of INH adherence as indicated by a positive urine isoniazid result\***

Characteristic	Median (IQR) or n (%) N=97	RR (95% CI)	p
<b>Infant Characteristics</b>			
Infant age (weeks)	6.3 (6.0-6.4)	1.0 (1.0-1.0) <sup>a</sup>	0.17
Weight-for-age Z (WAZ) score (at visit)	0.2 (-0.6-0.8)	1.3 (1.1-1.6)	0.002
Male	56 (57.7)	1.0 (0.7-1.5)	0.84
Received ARVs for PMTCT	95 (97.9)	0.5 (0.1-2.1)	0.34
Study visit	--	0.9 (0.8-1.0)	0.17
Time since enrollment (months)	2.1 (1.2-4.7)	1.0 (0.9-1.0)	0.16
<b>Maternal Characteristics on enrollment</b>			
Maternal age (years)	26 (24-30)	1.0 (1.0-1.1) <sup>b</sup>	0.51
Secondary education started	43 (44.3)	1.5 (1.1-2.2)	0.02
Maternal CD4 (cells/mm <sup>3</sup> ) <sup>c</sup> (n=83)	460 (313-646)	1.0 (1.0-1.0)	0.34
Maternal HIV RNA (copies/ml) <sup>c</sup> (n=89)	0 (0-0)	1.0 (1.0-1.0)	0.80
HIV viral load undetectable <sup>d</sup>	68 (76.4)	1.1 (0.7-1.6)	0.68
HIV viral load <1000 (copies/ml)	83 (93.3)	2.1 (1.1-4.0)	0.02
Maternal ART current use	97 (100)	--	--
Maternal ART initiation timing			
Before pregnancy	69 (71.1)	0.9 (0.6-1.4)	0.62
During/after pregnancy <sup>e</sup>	28 (28.9)	ref	
Maternal history of TB	10 (10.3)	0.8 (0.4-1.3)	0.35
Maternal IPT any use	73 (75.3)	1.3 (0.8-2.1)	0.33
Maternal IPT current use	26 (37.0)	0.7 (0.5-1.1)	0.11
Maternal IPT initiation timing			
Before pregnancy	20 (27.4)	0.9 (0.6-1.5)	0.72
During pregnancy	44 (60.3)	0.7 (0.5-1.1)	0.12
After pregnancy	9 (12.3)	ref	
<b>Residential Characteristics on enrollment</b>			
Persons in household	4 (4-4)	1.0 (0.8-1.2)	0.93
Rooms in household	2 (1-3)	1.1 (1.0-1.2)	0.13
Flush toilet in home	11 (11.3)	1.4 (0.9-2.2)	0.10
Electricity in home	65 (67.0)	1.1 (0.7-1.6)	0.79
Running water in home	20 (20.6)	1.1 (0.7-1.9)	0.70
<b>Caregiver-reported adherence at visit</b>			
	N=155		
Median time since last INH dose (hours)	15.1 (5.0-17.1)	1.0 (1.0-1.0)	0.20
Last INH dose (hours)			
<24	134 (86.5)	4.9 (0.8-28.9)	0.08
24-48	14 (9.0)	4.3 (0.7-25.4)	0.10
>48	7 (4.5)	ref	
Optimal INH use throughout the study <sup>f</sup>	93 (60.0)	0.9 (0.6-1.4)	0.78
Optimal INH use since last study visit <sup>f</sup>	149 (96.1)	3.7 (0.7-20.1)	0.13
No missed doses in past 3 days	136 (87.7)	2.4 (1.0-5.6)	0.05

<sup>a</sup> Age at study visit (per each additional week)

<sup>b</sup> Age (per each additional year)

<sup>c</sup> CD4 and VL data collected from routine programmatic data

<sup>d</sup> HIV viral load < 20 copies/ml

<sup>e</sup> Includes 1 mother who initiated ART after delivery but before study enrollment

<sup>f</sup> ≥ 90% reported adherence

\*Infant, maternal, and residential characteristics are from baseline with exception of weight-for-age (WAZ) score, study visit, and time since enrollment which is from the visit that urine testing occurred. Caregiver-reported adherence is from the visit that urine testing occurred.